Retrieved from Patel, F., Gan, A., Chang, K., et al (2023)
Within the findings were several considerations for patients and payers: High costs for GLP-1 medications ranked as respondents top concern (followed by lack of control over who is prescribed the medications) 93% covered GLP-1s for management of diabetes in the previous plan year
Back DiMarchi, R Efendic, S (1997) 'Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity', US Patent US6191102B1.Back Drucker, DJ, Habener, JF, Holst, JJ (1 Dec 2017) 'Discovery, characterization, and clinical development of the glucagon-like peptides', Journal of Clinical Investigation , 127/12, 4217-27
Ralph DeFronzo However, when you investigate the details, it becomes clear that these claims dont hold up
The commercial shortage period also revealed something important
Retatrutide remains investigational and is not FDA-approved, so patients should only consider it within legitimate clinical trial settings
